OCEA — Ocean Biomedical Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Ocean Biomedical Inc expected to post a loss of 15 cents a share - Earnings Preview
Brief: Ocean Biomedical Says On November 22 Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: Ocean Biomedical Says First Patients Dosed in Phase 1b Study of Novel Immunotherapy
Brief: Ocean Biomedical Announces Enrollment Of Patients For Phase 1b Study For Chronic Hepatitis B Treatment
Brief: Ocean Biomedical Inc Says Co Acquired A 50% Ownership Interest In Virion Therapeutics, Llc
Brief: Virion Therapeutics Co And Ocean Biomedical Entered Into A Joint Venture
Brief: Updated Ocean Biomedical Announces Non-Dilutive Amendment To Existing Agreement With Polar Multi-Strategy Master Fund
Brief: Ocean Biomedical Announces Loan Commitment From Largest Stockholder Up To $10 Mln
Brief: Ocean Biomedical Announces Newly Published Findings
Brief: Ocean Biomedical (Nasdaq Ocea) Announces New Patent For Anti-Fibrosis Discovery
Brief: Ocean Biomedical Extends Patent Rights For Breakthrough Idiopathic Pulmonary Fibrosis Discovery To Europe
Brief: Ocean Biomedical Inc Announces Malaria Vaccine Patent In Brazil
Brief: Ocean Biomedical, Inc. (Nasdaq OCEA) Announces Patent Award For Novel Cancer Immunotherapy Treatment
Brief: Ocean Biomedical Announces New Glioblastoma Results
Founder Dr. Jack A. Elias.
Brief: Ocean Biomedical Entered Into Loan Modification Agreement
Founder
Founder Dr. Jake Kurtis For Novel Malaria Vaccine Target
Brief: Ocean Biomedical And Aesther Healthcare Acquisition Announce The Award Of New Patents For Novel Monospecific And Bispecific Antibodies That Suppress Multiple Cancer Types